ToleroMune Grass Exposure Unit Study

2014-08-27 04:00:28 | BioPortfolio


Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy.

This study will look at the efficacy, safety and tolerability of three doses of ToleroMune Grass in grass allergic subjects following challenge with with grass in an Environmental Exposure Unit (EEU).


This study is designed as a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of ToleroMune Grass in grass allergic subjects with allergic rhinoconjunctivitis. The efficacy of ToleroMune Grass will be explored in subjects using an EEU (Environmental Exposure Unit).

The study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic, at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEU at least 3 days before randomisation.

In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be randomised to one of four groups and will receive treatment every 2 weeks (±2 days) for 14 weeks.

In Period 3, Post Treatment Challenge will consist of 4 visits to the EEU about 25 weeks after the first administration in the treatment period and assessments will be performed identical to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Grass Allergy


ToleroMune Grass, Placebo


Kingston General Hospital
K7L 2V7




Circassia Limited

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T04:00:28-0400

Clinical Trials [320 Associated Clinical Trials listed on BioPortfolio]

ToleroMune Grass Follow on Study

Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and...

Efficacy and Safety/Tolerability of Grass MATA MPL

Grass MATA MPL has been developed by Allergy Therapeutics (UK) Ltd. to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting grass ...

Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma

The purpose of this study is to determine whether it is safe to administer Grass-SPIRE to subjects suffering from both grass allergy and asthma

A Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using Mobile EECs

There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administe...

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the...

PubMed Articles [2097 Associated PubMed Articles listed on BioPortfolio]

Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.

BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B pr...

Intralymphatic immunotherapy with two concomitant allergens, birch and grass - a RDBPC trial.

Intralymphatic immunotherapy (ILIT) with only three lymph node-injections was performed with a combination of grass and birch allergen, with maintained safety and reduced reactivity at nasal grass all...

Grass-Allergic Children Frequently Show Asymptomatic Low-Level IgE Co-Sensitization and Cross-Reactivity to Wheat.

Specific immunoglobulin E (IgE) sensitization to wheat is more common than a doctor's confirmed wheat allergy and is also frequently observed in grass pollen-allergic patients (pollinosis patients). T...

Grass pollen production and group V allergen content of agriculturally relevant species and cultivars.

Grass pollen is the main cause of hay fever and allergic asthma in warm temperate climates during summer. The aim of this study was to determine the content of group 5 major allergens in pollen grains...

The molecular allergology of subtropical grass pollen.

Grass pollens are amongst the most important aeroallergen sources world-wide triggering allergic rhinoconjunctivitis and asthma in sensitised patients. Much of what we know about the allergen componen...

Medical and Biotech [MESH] Definitions

A genus of grass family (Poaceae) that include several rice species.

A plant species of the family POACEAE. It is a tall grass grown for its seed, corn, used as food and animal fodder.

A genus of saprobic mushrooms in the family Bolbitiaceae that grow in grass, dung, garden mulch, or in woods.

Genus in the grass family (Poaceae) including well known species Secale cereale (rye).

Annual cereal grass of the family POACEAE and its edible starchy grain, rice, which is the staple food of roughly one-half of the world's population.

More From BioPortfolio on "ToleroMune Grass Exposure Unit Study"

Quick Search


Relevant Topic

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Searches Linking to this Trial